支架内血栓形成：谁之过？ - Suppr

Suppr

超能文献

Stent thrombosis: who's guilty?

作者信息

Montalescot Gilles, Hulot Jean-Sébastien, Collet Jean-Philippe

出版信息

Eur Heart J. 2009 Nov;30(22):2685-8. doi: 10.1093/eurheartj/ehp436. Epub 2009 Oct 23.

DOI:10.1093/eurheartj/ehp436

PMID:19854727

Abstract

摘要

相似文献

Stent thrombosis: who's guilty?支架内血栓形成：谁之过？

Eur Heart J. 2009 Nov;30(22):2685-8. doi: 10.1093/eurheartj/ehp436. Epub 2009 Oct 23.

High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring.基于血小板功能监测，从氯吡格雷转换为普拉格雷治疗的经皮冠状动脉介入治疗患者中CYP2C19*2携带者的高频率。

Platelets. 2013;24(6):500-2. doi: 10.3109/09537104.2012.715218. Epub 2012 Aug 23.

Response to antiplatelet treatment: from genes to outcome.抗血小板治疗的反应：从基因到结果。

Lancet. 2010 Oct 16;376(9749):1278-81. doi: 10.1016/S0140-6736(10)61313-X.

Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.细胞色素P450 2C19功能丧失多态性与药物洗脱冠状动脉支架血栓形成的关系。

Am J Cardiol. 2009 Mar 15;103(6):806-11. doi: 10.1016/j.amjcard.2008.11.048. Epub 2009 Jan 24.

Bedside evaluation of thienopyridine antiplatelet therapy.噻吩并吡啶类抗血小板治疗的床旁评估

Circulation. 2009 May 19;119(19):2625-32. doi: 10.1161/CIRCULATIONAHA.107.696732.

Dual antiplatelet therapy after drug-eluting stents--how long to treat?药物洗脱支架置入术后的双联抗血小板治疗——应持续多久？

N Engl J Med. 2014 Dec 4;371(23):2225-6. doi: 10.1056/NEJMe1413297. Epub 2014 Nov 16.

Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient).血小板抑制剂：氯吡格雷（波立维）及近期获批的普拉格雷（Effient）的最新情况。

Gen Dent. 2010 Jan-Feb;58(1):7-9.

Can we override clopidogrel resistance?我们能否克服氯吡格雷抵抗？

Circulation. 2009 Jun 2;119(21):2854-7. doi: 10.1161/CIRCULATIONAHA.108.857722.

Duration of clopidogrel therapy with drug-eluting stents.药物洗脱支架的氯吡格雷治疗持续时间。

N Engl J Med. 2010 Jul 29;363(5):489; author reply 490. doi: 10.1056/NEJMc1005624.

Prasugrel versus clopidogrel.普拉格雷与氯吡格雷的比较。

N Engl J Med. 2008 Mar 20;358(12):1298-9; author reply 1299-301.

引用本文的文献

Three-Year Clinical Outcomes With the Cilotax Dual Drug-Eluting Stent vs Everolimus-Eluting Stents in Patients With Acute Myocardial Infarction.急性心肌梗死患者中 Cilotax 双药物洗脱支架与依维莫司洗脱支架的 3 年临床结果。

Tex Heart Inst J. 2024 May 1;51(1). doi: 10.14503/THIJ-23-8271.

Efficacy and Safety of Dual-Drug-Eluting Stents for de Novo Coronary Lesions in South Korea-The Effect Trial.韩国双药洗脱支架治疗初发冠状动脉病变的疗效与安全性——效应试验

J Clin Med. 2020 Dec 27;10(1):69. doi: 10.3390/jcm10010069.

The new biology: a bridge to clinical cardiology.新生物学：通往临床心脏病学的桥梁。

Hippokratia. 2012 Apr;16(2):106-12.

CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.在接受冠状动脉支架置入术的中国人群中，CYP2C19 表型、支架血栓形成、心肌梗死和死亡率。

PLoS One. 2013;8(3):e59344. doi: 10.1371/journal.pone.0059344. Epub 2013 Mar 12.

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.CYP2C19 基因变异对氯吡格雷抗血小板治疗临床疗效的影响：系统评价和荟萃分析。

BMJ. 2011 Aug 4;343:d4588. doi: 10.1136/bmj.d4588.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验